<SEC-DOCUMENT>0001104659-19-058334.txt : 20191031
<SEC-HEADER>0001104659-19-058334.hdr.sgml : 20191031
<ACCEPTANCE-DATETIME>20191031160614
ACCESSION NUMBER:		0001104659-19-058334
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191031
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191031
DATE AS OF CHANGE:		20191031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		191183693

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm1921482d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C.
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION
13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE
ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date
of earliest event reported): October 31, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Sciences,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant
as Specified in Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 33%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or
        Other Jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of Incorporation)</P></TD>
    <TD STYLE="width: 34%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission
        File Number)</P></TD>
    <TD STYLE="width: 33%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification
        No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">50 Health Sciences
Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Stony Brook, New
York 11790</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal
Executive Offices) (Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">631-240- 8800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s
telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former
Address, if Changed Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material
    pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    <BR>
    Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001 par value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APDN</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Capital Market</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase Common Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APDNW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.03.</B></TD><TD STYLE="text-align: justify"><B>Amendments
                                         to Articles of Incorporation or Bylaws; Change in Fiscal Year.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At a Special Meeting
of Stockholders (the &ldquo;<B><I>Special Meeting</I></B>&rdquo;) held on October 31, 2019, the stockholders of Applied DNA Sciences,
Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) authorized the board of directors of the Company (the &ldquo;<B><I>Board</I></B>&rdquo;),
in its discretion, to amend the Company&rsquo;s Certificate of Incorporation, as amended (the &ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;),
to effect a reverse split of the Company&rsquo;s outstanding common stock, par value $0.001 (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
at a ratio between one-for-fifteen (1:15) and one-for-fifty (1:50), with such final ratio to be determined by the Board. The Board
determined to set the reverse stock split ratio at one-for-forty (1:40) (the &ldquo;<B><I>Reverse Stock Split</I></B>&rdquo;)
and approved the final form of the Certificate of Amendment to the Certificate of Incorporation to effectuate the Reverse Stock
Split (the &ldquo;<B><I>Certificate of Amendment</I></B>&rdquo;). The Certificate of Amendment was filed with the Secretary of
State of the State of Delaware on October 31, 2019, and the Reverse Stock Split will become effective in accordance with the terms
of the Certificate of Amendment at 12:01 a.m. Eastern Time on Friday, November 1, 2019 (the &ldquo;<B><I>Effective Time</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time,
every 40 shares of Common Stock issued and outstanding will be automatically combined into one share of issued and outstanding
Common Stock, without any change in the par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fractional shares
will not be issued as a result of the Reverse Stock Split. Instead, any fractional shares of the Company&rsquo;s Common Stock
that would have otherwise resulted from the Reverse Stock Split will be rounded up to the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">American Stock Transfer
and Trust Company, LLC is acting as exchange agent for the Reverse Stock Split, and will send instructions to stockholders of
record who hold stock certificates regarding how to exchange existing stock certificates for new book-entry statements reflecting
the post-reverse split shares of Common Stock. Stockholders who hold their shares in brokerage accounts or &ldquo;street name&rdquo;
are not required to take any action and will see the impact of the Reverse Stock Split automatically reflected in their accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Common Stock is
expected to begin trading on The Nasdaq Capital Market (&ldquo;<B><I>Nasdaq</I></B>&rdquo;) on a Reverse Stock Split-adjusted
basis on Friday, November 1, 2019. There will be no change in the Company&rsquo;s Nasdaq ticker symbol, &ldquo;APDN&rdquo;. In
connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 03815U300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock
Split results in a proportionate adjustment to the per share exercise price and the number of shares of Common Stock issuable
upon the exercise of outstanding stock options and warrants, as well as the number of shares of Common Stock eligible for issuance
under the Company&rsquo;s 2005 Incentive Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate
of Amendment that effectuated the Reverse Stock Split, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.07.</B></TD><TD STYLE="text-align: justify"><B>Submission
                                         of Matters to a Vote of Security Holders.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 31, 2019,
the Company held the Special Meeting. The following proposals were voted on and approved by the Company&rsquo;s stockholders at
the Special Meeting with the stockholders&rsquo; final voting results as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Proposal 1</U></B> &ndash; Approval
of the Amendment to the Company&rsquo;s Certificate of Incorporation to Effect a Reverse Stock Split of Common Stock at a Ratio
in the Range From One-For-Fifteen to One-For-Fifty, with such Specific Ratio to be Determined by the Company&rsquo;s Board of
Directors Following the Special Meeting (the &ldquo;<B><I>Reverse Stock Split Proposal</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The final voting results of the vote taken
at the Special Meeting with respect to Proposal 1 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 24%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>For</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 28%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Against</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 25%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Abstain</B></P></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Broker
        Non-Vote</B></P></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,210,570</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,415,588</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,405</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Proposal 2</U></B> &ndash; Approval,
if Necessary, of the Adjournment of the Special Meeting to Solicit Additional Proxies in Favor of the Reverse Stock Split Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The final voting results of the vote taken
at the Special Meeting with respect to Proposal 2 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 24%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>For</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 28%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Against</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 25%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Abstain</B></P></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Broker
        Non-Vote</B></P></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,455,668</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,920,462</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 1pt; padding-left: 2pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">386,433</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 7.01.</B></TD><TD STYLE="text-align: justify"><B>Regulation
                                         FD Disclosure.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 31, 2019,
the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information furnished
pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), or otherwise subject to the liabilities
under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial
                                         Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following exhibits
are being filed or furnished herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(<I>d)</I></TD><TD STYLE="text-align: justify"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 85%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tm1921482d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-top: 3pt"><A HREF="tm1921482d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Certificate of Amendment to the Certificate of Incorporation</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tm1921482d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-top: 3pt"><A HREF="tm1921482d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    release of Applied DNA Sciences, Inc. dated October 31, 2019</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    DNA Sciences, Inc. </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)
    </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James A. Hayward </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. Hayward <BR>
    Chief Executive Officer </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">Date: October 31, 2019</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm1921482d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.1<BR>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH CERTIFICATE OF AMENDMENT<BR>
TO THE<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
APPLIED DNA SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Applied DNA Sciences, Inc. (the &ldquo;<B>Corporation</B>&rdquo;),
a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FIRST:</B> Article IV of the Certificate of Incorporation,
as amended (the &ldquo;<B>Certificate of Incorporation</B>&rdquo;), of the Corporation is hereby amended by adding the following
paragraph at the end thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">&ldquo;Upon the filing and effectiveness (the &ldquo;<B>Reverse
Split Effective Time</B>&rdquo;) pursuant to the DGCL of this Certificate of Amendment to the Certificate of Incorporation of the
Corporation, each forty (40) shares of the Corporation&rsquo;s Common Stock, par value $0.001 per share, issued and outstanding
immediately prior to the Reverse Split Effective Time, shall automatically be reclassified, combined, and converted into one (1)
validly issued, fully paid, and non-assessable share of Common Stock, par value $0.001 per share, of the Corporation, without any
action by any holder thereof; provided that no fractional share interests shall be issued as a result of the foregoing reclassification,
combination, and conversion. Any stockholder of record of Common Stock immediately prior to the Reverse Split Effective Time that
would otherwise be entitled to fractional share interests pursuant to the provisions of this Article, shall be entitled, upon the
Reverse Split Effective Time, to receive one whole share of Common Stock in lieu of such fractional share interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">From and after the Reverse Split Effective Time, certificates
that, immediately prior to the Reverse Split Effective Time, represent shares of Common Stock that are held by any stockholder
shall thereafter represent the number of shares of Common Stock into which such shares shall have been reclassified, combined,
and converted at the Reverse Split Effective Time pursuant to this Certificate of Amendment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECOND:</B> This Certificate of Amendment shall become effective
on Friday, November 1, 2019, at 12:01 a.m.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>THIRD:</B> That pursuant to resolution of the Board of Directors,
the proposed amendment was submitted to the stockholders of the Corporation for consideration at the special meeting of stockholders
held on October 31, 2019 and was duly adopted by the stockholders of the Corporation in accordance with the applicable provisions
of Section 242 of the General Corporation Law of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><B>IN WITNESS WHEREOF</B>, the Corporation
has caused this Fourth Certificate of Amendment of Certificate of Incorporation to be signed by its Chairman, President and Chief
Executive Officer on Thursday, October 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>APPLIED DNA SCIENCES, INC. </B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;James&nbsp;A.&nbsp;Hayward &nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm1921482d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>Applied DNA
Sciences Announces 1-for-40 Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #444444"><FONT STYLE="background-color: white"><B><I>-
</I></B><I>Common Stock to Begin Trading on a Split-Adjusted Basis at Market Open on Friday, November 1, 2019 -</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>STONY BROOK, N.Y., October 31, 2019</B>&nbsp;&ndash;&nbsp;Applied
DNA Sciences, Inc.&nbsp;(NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &ldquo;Company&rdquo;), a leader in polymerase chain reaction
(PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it will effect a 1-for-40
reverse split of its outstanding common stock effective at 12:01 AM Eastern Time on Friday, November 1, 2019. The Company&rsquo;s
common stock will begin trading on a split-adjusted basis when The Nasdaq Capital Market opens on Friday, November 1, 2019 under
the existing symbol &ldquo;APDN.&rdquo; Applied DNA&rsquo;s common stock will trade under a new CUSIP number, #03815U300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">This
announcement of the reverse stock split follows the Company&rsquo;s special meeting of stockholders on October 31, 2019, at which
the stockholders approved an amendment to the Company&rsquo;s certificate of incorporation to implement a reverse split of its
common stock, at a ratio in the range of 1-for-15 to 1-for-50 shares, and authorized the Company&rsquo;s board of directors to
determine the specific ratio. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The reverse stock split is intended
to increase the per share trading price of Applied DNA&rsquo;s common stock to satisfy the $1.00 minimum bid price requirement
for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &ldquo;Bid Price Requirement&rdquo;),
and the terms of the Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;) decision dated October 1, 2019, which requires that the Company
evidence compliance with all applicable criteria for continued listing on or before December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company can provide no assurance
that the market price of its common stock will sufficiently increase following the reverse stock split to satisfy the Bid Price
Requirement. Even if the reverse stock split results in a closing bid price in excess of $1.00 per share, there can be no assurance
that the market price of the Company&rsquo;s common stock following the reverse stock split will remain above the minimum level
required to evidence full compliance with that requirement; that is, a closing bid price of at least $1.00 per share for a minimum
of ten, but generally not more than 20, consecutive business days. The Company must also evidence compliance with the applicable
$2.5 million stockholders&rsquo; equity requirement for continued listing on Nasdaq by no later than December 31, 2019, and as
such may remain at risk for delisting notwithstanding the reverse stock split and/or timely satisfaction of the Bid Price Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The reverse stock split will impact
all holders of Applied DNA&rsquo;s common stock uniformly and will not impact any stockholder&rsquo;s percentage ownership interest
in the Company; however, no fractional shares will be issued in connection with the reverse stock split, and any fractional shares
resulting from the reverse stock split will be rounded up to the nearest whole share. Furthermore, the reverse stock split will
not affect any stockholder&rsquo;s proportionate voting power, subject to the treatment of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the effective time of the reverse stock split, every 40 shares
of APDN common stock will convert into one newly issued share of APDN common stock, without any change in the par value of $0.001
per share. The reverse stock split will reduce the number of shares of Applied DNA&rsquo;s outstanding common stock from 48,015,938
shares to approximately 1,200,399 shares. Proportional adjustments will be made to Applied DNA&rsquo;s outstanding stock options
and outstanding warrants (both publicly-traded and privately held).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;The reverse split has had very
solid support from stockholders, and from the board of directors. We believe the change in capital structure can strongly benefit
our stockholders,&rdquo; stated Dr. James A. Hayward, Chairman, President and CEO of Applied DNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After the effective time of the reverse stock split, stockholders
of shares of common stock held in book-entry form or through a bank, broker or other nominee do not need to take any action in
connection with the reverse split and will see the impact of the reverse split automatically reflected in their accounts. Beneficial
holders are encouraged to contact their bank, broker or nominee for more information. Stockholders of record with shares held in
certificate form will receive instructions from Applied DNA&rsquo;s exchange agent, American Stock Transfer &amp; Trust Company,
LLC, regarding how to exchange existing stock certificates for new book-entry statements reflecting the post-reverse split shares
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional information about the reverse stock split can be
found in the Company&rsquo;s definitive proxy statement filed with the Securities and Exchange Commission on October 8, 2019,
a copy of which is available at <FONT STYLE="color: Blue"><U>http://www.sec.gov</U></FONT> or at the Company&rsquo;s website at
<FONT STYLE="color: Blue"><U>https://adnas.com/molecular-based-security/investors/sec-filings/</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>About Applied DNA Sciences</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells
and the development of pre-clinical&nbsp;nucleic&nbsp;acid-based&nbsp;therapeutic drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Visit&nbsp;<FONT STYLE="color: Blue"><U>adnas.com</U></FONT>&nbsp;for
more information. Follow us on&nbsp;Twitter&nbsp;and&nbsp;LinkedIn. Join our&nbsp;mailing list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common stock listed on NASDAQ under the symbol APDN, and warrants
are listed under the symbol APDNW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Forward-Looking Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
</B>The statements made by Applied DNA in this presentation may be &ldquo;forward-looking&rdquo; in nature within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. Forward-looking statements describe Applied DNA&rsquo;s future plans, projections, strategies and expectations,
and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied
DNA. Actual results could differ materially from those projected due to substantial doubt relating to Applied DNA&rsquo;s ability
to continue as a going concern, uncertainties relating to its ability to maintain its NASDAQ listing after December 31, 2019 in
light of delisting notices received and its recent hearing, the possibility of failure to make timely payment on its outstanding
secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all
of Applied DNA&rsquo;s assets, its history of net losses, limited financial resources, limited market acceptance, its ability
to penetrate key markets, the uncertainties inherent in research, development, and regulatory approval for Applied DNA&rsquo;s
or its partners&rsquo; product candidates, shifting enforcement priorities of U.S. federal laws relating to cannabis,&nbsp;its
ability to satisfy the Bid Price Requirement following the reverse stock split discussed herein, and various other factors detailed
from time to time in Applied DNA&rsquo;s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18,
2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and
other reports we file with the SEC, which are available at&nbsp;<FONT STYLE="color: Blue"><U>www.sec.gov</U></FONT>. Applied DNA
undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>investor contact:&nbsp;</B>Sanjay M. Hurry, LHA Investor
Relations<B>,&nbsp;</B>212-838-3777,&nbsp;shurry@lhai.com<BR>
<B>web:&nbsp;</B><FONT STYLE="color: Blue"><U>www.adnas.com</U></FONT><BR>
<B>twitter:&nbsp;</B>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ ^@#Z  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S 2P# 2(  A$! Q$!_\0
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M=:M97&BFZTH0)XGL?B%HZ)<65PWB:\\/:OXRU+PWI&JW/AV]L)0#]KOV+/\
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M[U]-UC2[;4(8-5UO7VTS4[75=(O=8TKP])X?;6='OK"UUNZ,1<>-:II32_\
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MH5_I6E:M<3VNGW\D/BWP_H#7=I-<P26PFLC=,DZ&.<++DM^'_D?MQ@D#0/\
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M->J!$4L510SLK.P #.RJJJSD<LP554%B2%51T %+@8QC@# 'L.GY4 ?R?_\
M!OO^S;^SE^TK^R7^U'8?'OX&?"#XUV_AO]O[XRW7A^'XI_#SPCX]?0YCX,^&
M<#SZ7-XCTK4;G3EG>"2*YBM)8+>:2*Y)CWRS[OZA-)^&'P]T#P+'\+] \#>"
M]!^&D.AWGA>+X=Z+X4T+2_ L7AG4;>>TU'P_'X3L;&WT&/1K^VN9[>]TM; :
M;<P32QO9_O6-=VJ(F[8BKO;<VU0NYL!=S8 RVU57<><*HS@##J /G:Y_9'_9
M;O/A'I?[/]W^S9^S_=? ;1-376-'^"-Q\&_A]-\(-*U(:G?:Q_:.F_#230&\
M&V.H_P!IZE?ZDMY;Z.DJ:C=W-ZO[Z>0MZ7XQ^%_P\^(G@V^^'7Q#\!^"/'OP
M]U.SM]/U+P'XS\)Z'XH\%ZA86@B6TL;SPMKEEJ&AW-E;B&+R;2:QDAA:-/)6
M-5"COJ* /"O@O^S)^S[^SEINH:-\ ?@G\)_@MI>L2PSZS:_"_P"'OA7P/_;,
MUN%$,VL3>&]+TV?598AO6&74)+B:V5Q';R11*L8;\:/V8OV>?VCK+2M._: ^
M!OP@^-ECH4DTNAV_Q5^''A+QX-$EN&BDN)-'E\2Z5J-QI<DSV\!F;3YK7SUC
M5;CSMD;)[O10!Y_X*^''@7X7^%=,\#?#/P9X2^'G@S0E,>C>$O!'AO2/"GAC
M2HI)))W32M!T&VT[2]/WSRO+,UO;))/)B61FN,3#S3XB?LM?LY?&#Q%9^+/B
MS\!O@Q\3/$UA%'!:^(/'GPL\(>*=<C@BP(K:35-6TNZN;BRCVAH[*X>6SC94
M:"&W,?S?1#1H^0RAL]<C/;'\A0(T48"@ =AD5KAZ^)PE55\)C,=A,1RS@\1@
M<=BL!6E2FI1=&<\)6HRJ4N27*X3DU))<R?3FQ.$P^,IJEBJ&%Q-'FC+ZOC<%
MA<?1C.$E*-2G'%4JGLZG,E+FBERR^%JVO%:]\/O!'B;P;J'P[\1^#O"NO^ =
M7T8^'M4\#ZUX=TG4_!^HZ \:PMHEYX;O[:?1[C2# @@.FRV;6;1A4,1"JHYZ
M^^"GPBU3X:K\%M3^%GP\U'X/0Z78:)#\*;[P7X>N_AI'HND7EKJ.EZ0G@>YL
M)?#8T_3+ZQM+S3[,Z<;6RN;:"6VBC:&/'K&U<8QT_P ]>M&T>G8#\!TJ?;8J
M].V,QB5+$?6J?+BJ]/V6)LE]:C[.HN;%627MY6JM*-ZKY8N(\)AGS7P^&?/1
M^JU>;#4)JKA+M_59*4+1PW-*4O8*])2DVH*[1P$GPW\!S>"4^&T_@OPC<?#J
M+0K?PLG@*Z\,:+<^"QX8M8%LK?PXOA62S;13H4%G&EI#I;61L8K9!"EN$"JO
MAUA^Q'^QYIVAWGA>P_96_9VM?#>H:M9:]?:&/@I\/9-+NM<TPW']EZO+9W&@
M30/J&E"ZG&DW+(9-+\Z;^S_LIE8U]7[5Z8_S]>M-\J,'.Q<YSG'.?7]*Z*.8
M9GAU.%#-,TH4ZU6%7$4L-F>.PE"M.'M+3K8?#8FE2KSO4FVZT9MN4FYW;OE4
MRW 5IT9U<!EU1X>+A1=?+L%BZE.#45RTZV)H5*M)<L()*FXJ*C%*RBK?*?Q?
M_8?_ &0/V@_%5MXT^./[+W[/_P 6O&MG#!;P^,?B#\)/!?BGQ*]E8KY5GIUW
MKFK:5<ZI?Z=;1.\$&F:A=7>G1V[20I9K#+-'+]'Z9X5\.Z-X?LO"6DZ#HFF>
M%--TE- T[PQIVDV%AX=L-"AMA90:+9Z'9V\&F6^DQ6:K9IIL5JEFELB0QPI&
MNVN@  Z#MBEKCBFHQ3=VDDWW>MV]KMW5V]6U=ZL[M%91BHI*R2VT[+HO[JT7
M0^:O"O[&O[)/@2_\:ZIX%_9<_9S\$:G\2?"^N^!_B+J'@_X(_#7PS>_$#P5X
MHDAF\2^$?&]WHOAJRN/%/AK7YH(IM7T76I+VPU"5$>[AF8$MZCX#^$OPQ^%O
M@?3?AE\,OAUX#^'7PVT>WU&STGX>^!/"&@>$O VG66L75Y>ZO9V/A/0K"QT.
MTM=4N]0O+S4+:WLHX+R\N)KFXCDDED+^B44P/F/X9_L6_LD?!?QI>_$7X0?L
MR?L_?"WQYJ(NA>>,?A[\'? 'A#Q*XOEVWHM]9T/0;*_LEOL(;^.TGBAOF4O=
M0RN0R^CZI\#?@YK?Q0\/?&[6/A1\--7^-'A#1KOP[X1^+^J^ _"VH_%'PIH%
M_%K%M?:%X;\?76ER^)]$T6]M-?UJRO=,TS4[6UOK35M3MKM)HK^Y63U6B@#R
MMO@C\(7^*G_"]7^%GPU/QN'AIO!:?&)? GA@?%*/P8[>:WA)/B ^F2>*T\-&
MXS<_V$FJKI9G/FFT,FYWY/XK?LI_LS?'J]L]2^.W[/'P(^-FHZ9:O9Z7J/Q:
M^#_P^^(FHZ5:22"22TTV_P#%OA_5;NRL]X#)!;RIM<"1GD8*5^@** /(OBA\
M _@K\;_!\/P]^,WPE^&?Q7\ VLUO/9^"OB+X#\+>-/"]A<6=M):6-UIVB^(]
M*U&PTZ]L()9(=/O;*""ZL(2([.6#&ZK/PN^"/PB^!_A6+P+\%_A?\.OA)X*C
MN);K_A$_AKX+T#P1X?DN9HU2:\GTKPY8Z=8W5_<^7']MO[J":XO5WBX9V=F/
MJE% 'R'X-_8"_8@^'7Q$M/BYX!_9"_9G\%?$W3[P:AIGC?PK\$?AYH/B#1M1
MRI?5="O=,T&V?0];F*C[1K>D_8]3N06^TW,Q=B?K:*(QEB6#%@N2%*C(W%C@
MLQ +,2%W$*/5BS--10 R1-ZE=S+G'S*<,,$'@]1G&"1AL$[64X(_.?\ :Z_X
M)/\ ["7[;CZCJ_QR^!GAP_$*_BQ_PN#X?JWP]^*\=RD:107EYXN\."WD\3O:
M1H$L[7QO:>*=.MP65+((=@_1NO,_C%\0&^%/PM^)7Q-&@ZSXJ'PZ^'GC3QZ/
M"OAV%[C7_$P\'^'=1\0RZ!HD,<,[2ZQJL>G&PTJ)8IY);RYC$5K=R!82 ?QL
M_M/_ /!JAXZT9[SQ#^R%^TCHOC2"U-Q)IOP]^/\ I3^%?$]L$R]O!IOQ0\#0
M7&BWU](K&%9-9\ ^&V+;GEUA8G"+^(OQ!^#O[8G_  33^(&C6?[7?[)WAS6]
M#UJXO++1=&^-0N_%7@#QI'I%O!/J4_@?XH?!SXAZ1K5OJ%C!?Z;<23VWC$FP
M6Y@AUKPW<3E[>+]//%?_  7-_P""PO\ P4*U>Y\!_L1_"/4_AMIFH*]K<:=^
MS?\ #?4/B[XYTS3[QQ !XE^,?BS0]4\(^#Y8C<0K_P )!%HWP]>TF42)<VJ;
MKJO2/@'_ ,&V/[;W[3GB]OB]_P % ?CV?AI>Z]/%=Z_#/XFD^/\ ^T)K%J7)
MGTZ_\5WVJ3^ _"<TD&RVCGCU_P"(<&FCS4M-#M6C51ZF5Y]GV1U*D\DSO-LG
ME6BHU)Y;F>;Y>Y6ZO^RLWRFJVUHW[57M&[=K'EYCD>2YQ[-9OE.69FJ+O36.
MRO*<9*+[>UQV58ZLH+6T%54(MMQA%RDY?E9\;_VT_@'\</ WA'X1_LL_\$W/
M"/P6^-OCB\L]&OO%VA_$_P"+OQP\3ZG?W,VW3-*^"'@2^>Q-OKNIW"G[/?:[
M9>-=4L@\EEX>M RVVO']Z?\ @DO_ ,&\&FZ#HTWQO_X*->$$O_$?B+2?+\ ?
MLX1^)K^VD\"1:DLS7/BWXH>(?".MVTVH^.;FQN&M]%\)6NLWMCX4M-0U:;Q#
M>:MXDOA:>&OZ"OV)/^"8G[''[ VFR?\ "@OA%86'CB]LWL=?^,'C*\D\:?%S
MQ-#)L%PMYXPU-/\ B0:;>L@FN/"_@NS\->$_.VW":%'<F6:;] A;PC@1J!UP
M!@?D,"NW'\8<7YE7P6(QO%G%>-J9;K@)XKB3-9SP\XJT*D&L2TJD8\RNDHKF
M;23;,</PUPS@:.(HY=P[E& IXZ#AF%/#Y?E488A/E;B^3)\/)P<HIN,YRYK*
M\79-?E5'_P $6_\ @F0_ _9CTEB,<'Q_\5.,Y.,_\)PH/?H.V>*D'_!%C_@F
M6.?^&8=(_'Q]\4S^A\=8K]4Q#&I)" 9X/7G'3/-+Y:?W17H/Q%\1)._^OW&:
MT2M_K-G#225DE_MJT2T6BT1Y$_#[@:K)SJ<&\*3F[)RJY!E=:;LK)RJ/!Q;T
MZ6TVUW/RL/\ P18_X)EGK^S#HXQZ>/OBD/Y>.A7WS\&/@I\./V>_AIX9^#_P
M=\+Z=X)^''@^/4X_#7ABPDO+BUTV/6=:U'Q#J;"YU*\O;^YGU#6=6U'4[RYN
M[J>:XO;VXF=_G 'K7EI_=%.VJ.P_(5Y.;<3\49]2I4,\XFS_ #FCAZDJU"EF
MN:XS,:="K*'LY5:,,97KQI5)4_W<IPC&4H)0;<58]'*^%>&\CJU:V3</Y'E5
M6O3C2K5,LRO"9?4K4XS=2-.K/#4:<JL(S;G&$VXQFW))-W%HHHKQ#Z ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "J%T \BHPRF8VVGIN1+N:-O]Z.6"*1&ZHZ!E(.<E% &%H.CZ1H%K'I^@
MZ3I6A:>\LUT]AHNG66E6375PUN\]RUI806\!GF8EI9C&9)#R[' KIH?ND>A
?&>3C8AY)Y/7J23CCH!110!-1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
